Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, presented its top-line final data from the Phase II clinical trial of PV-10 for metastatic melanoma. Results were showcased at the second European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany. Key final data from the 80 subjects in the Phase II study include an objective response rate of 50 percent in subjects' target lesions (25 percent complete response and 25 percent partial response); 70 percent disease control in these lesions (combined complete, partial, and stable response subjects); and 33 percent of subjects having an untreated bystander melanoma lesion achieved an objective response rate in their bystander lesions while 50 percent achieved disease control in these lesions. Analysis of temporal data showed that Stage III subjects also experienced significantly greater mean progression-free survival (PFS) of at least 9.6 months, versus 3.1 months for Stage IV subjects. Median PFS for Stage III subjects was not reached during the 12-month study interval; The full presentation shows strong response rate and PFS results, and Stage III melanoma patients are expected to be the targeted patient population for Phase III.